DadFinStart your free weekEntrada Therapeutics, Inc. (TRDA) stock score
$4.89 ▲ +7.47% today
Entrada Therapeutics, Inc. (TRDA) is a Biotechnology company in the Healthcare sector, listed in the United States. On DadFin's weekly run it scores 11.8 out of 100 on the Dad Score, a poor reading that places the business ahead of 12% of the 5,699 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #869 of 954. Its strongest axes are conviction and macro; its weakest are valuation and quality.
Scores from the run of Nov 7, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →
The eight axes
Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.
Key numbers
What subscribers see on TRDA
- Value Score: is the price right for this business, the score the Value book is selected on.
- Trader Score: is it set up to move, refreshed every 30 minutes in the session.
- The full eight-axis breakdown, every input and its percentile.
- SEC filings, insider buying, earnings history and peers side by side.
- Whether it is in this week's published books, with the receipts.
Biotechnology peers
| Stock | Company | Dad Score | Band |
|---|---|---|---|
| VRTX | Vertex Pharmaceuticals Incorporate | 85.8 | strong |
| MRNA | Moderna, Inc. | 35.7 | weak |
| REGN | Regeneron Pharmaceuticals, Inc. | 95.8 | strong |
| ARGX | argenx SE | 95.8 | strong |
| ONC | BeOne Medicines AG | 98.1 | strong |
| RVMD | Revolution Medicines, Inc. | 57.0 | middling |
| RPRX | Royalty Pharma plc | 99.7 | strong |
| GMAB | Genmab A/S | 68.2 | middling |
Prices from DadFin's live feed (refreshed about every 30 minutes in the session); scores from the weekly run of Nov 7, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.